

Partners

1. Eberhard Karls Universität Tübingen (www.uni-tuebingen.de)
2. Università degli Studi di Modena e Reggio Emilia (www.unimore.it)
3. Lunds Universitet (www.lu.se)
4. Haskoli Islands (www.hi.is)
5. RISE Process Development (www.ri.se)
6. InoCure (www.inocure.cz)
7. PamGene (www.pamgene.com)

Partner Organisations

1. Oculis ehf. (www.oculis.com)
2. InnoSer BV (www.innoser.eu)
3. 2-BBB Medicines BV (www.2-bbb.com)
4. Biolog Life Science Institute (www.biolog.de)
5. Hannover Clinical Trial Center (www.clinical-trial-center.de)
6. NLO European Patent and Trade-mark Attorneys (www.nlo.eu)
7. European Vision Institute (www.europeanvisioninstitute.org)

Scientific Coordinator

Dr. François Paquet-Durand

Cell Death Mechanisms Group
Institute for Ophthalmic Research

Elfriede-Aulhorn-Straße 7
72076 Tuebingen, Germany

Phone: +49 7071 29 874 30
E-mail: francois.paquet-durand@uni-tuebingen.de

Managing Coordinator

Dr. Sigrid Diether

Research Management Unit
Institute for Ophthalmic Research

Elfriede-Aulhorn-Straße 7
72076 Tuebingen, Germany

Phone: +49 7071 29 84018
E-mail: sigrid.diether@uak-swm.de

www.transmed-itn.eu



transMed receives funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765441

Educating the next generation of
scientists in translational medicine:
Focus on eye diseases

*trans***Med**




The challenge

Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed therapies. This is very clearly so in blinding retinal degenerations (RDs), where most are yet untreatable. To address this problem, transMed pursues an innovative programme to educate “translational researchers” that focuses on the bench-to-bedside development of treatments for RD.

transMed joins researchers from academia and industry, who contribute specific critical expertise to a curriculum covering all major aspects of translational research:

From basic research into disease mechanisms and target definition, to drug design and development, in vitro and in vivo disease models, drug delivery systems, biomarkers, good manufacturing practice, toxicological testing and pharmacokinetics, regulatory affairs, intellectual property, all the way to clinical trials and commercialisation.



PhD training in translational medicine

transMed integrates projects from different pre-clinical and clinical stages, to give its PhD students a broad overview in translational research.

The training is completed by e-lectures, the inclusion of dedicated conferences for young researchers, a secondment and hands-on course programme from industry to academia and vice versa, permitting further insight and networking in the European biotech industry.

Altogether, transMed allows its students to obtain a competitive PhD degree in critical areas of biomedical research, providing for a strong employability in both the private and public sector.